Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus

R Pop-Busui, E Oral, D Raffel, J Byun, V Bajirovic, A Vivekanandan-Giri, A Kellogg, S Pennathur, Martin Stevens

    Research output: Contribution to journalArticle

    19 Citations (Scopus)

    Abstract

    Cardiovascular disease, the leading Cause of death in patients with type 2 diabetes mellitus (T2DM), is usually preceded by endothelial dysfunction and altered myocardial blood flow (MBF) regulation. Hyperglycemia, oxidative-nitrosative stress, systemic inflammation, and insulin resistance are implicated in the pathogenesis of abnormal MBF regulation, myocardial ischemia, and apoptosis. However, the impact of oral antihyperglycemic therapy on myocardial perfusion is controversial. Our objective was to explore the effect of rosiglitazone and glyburide oil nitrosative stress and MBF regulation in Subjects with T2DM. [N-13]ammonia positron emission tomography and cold pressor testing were used in 27 diabetic subjects (mean age, 49 +/- 11 years; glycohemoglobin, 7% +/- 1.5%) randomized to either rosiglitazone 8 mg/d or glyburide 10 mg/d for 6 months. Isotope dilution gas chromatography-mass spectrometry was used to quantify plasma 3-nitrotyrosine, a stable marker or reactive nitrogen species. At 6 months, there were no significant differences between groups in the mean glycohemoglobin, blood pressure, or plasma lipids. Rosiglitazone significantly reduced plasma nitrotyrosine, high-sensitivity C-reactive protein, and von Willebrand antigen (P
    Original languageEnglish
    Pages (from-to)989-994
    Number of pages6
    JournalMetabolism
    Volume58
    Issue number7
    DOIs
    Publication statusPublished - 1 Jul 2009

    Fingerprint

    Dive into the research topics of 'Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus'. Together they form a unique fingerprint.

    Cite this